CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines Novel percutaneous interventional therapies in heart failure with preserved ejection fraction: an integrative review Sleep quality and risk of coronary heart disease-a prospective cohort study from the English longitudinal study of ageing A Score to Assess Mortality After Percutaneous Mitral Valve Repair Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EACVI), European Heart Rhythm Association (EHRA), and European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the ESC Cardiovascular risk prediction in type 2 diabetes: a comparison of 22 risk scores in primary care settings

Clinical Trial2018 Oct 22;17(1):137.

JOURNAL:Cardiovasc Diabetol. Article Link

Cardiac resynchronization therapy with a defibrillator (CRTd) in failing heart patients with type 2 diabetes mellitus and treated by glucagon-like peptide 1 receptor agonists (GLP-1 RA) therapy vs. conventional hypoglycemic drugs: arrhythmic burden, hospitalizations for heart failure, and CRTd responders rate

Sardu C, Paolisso P, Sacra C et al. Keywords: cardiac resynchronization therapy with defibrillator; diabetes mellitus; arrhythmic burden; heart failure

FULL TEXT PDF